We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why OKLO Is Betting Big on the Future of Nuclear Isotopes
Read MoreHide Full Article
Key Takeaways
OKLO's isotopes business targets rising demand in medicine, manufacturing, research, space and security.
OKLO plans to reprocess existing materials and produce fresh isotopes in purpose-built reactors.
Groves could move toward fuel loading and first criticality after final reviews, targeted for July 2026.
Oklo Inc.’s (OKLO - Free Report) isotopes business is becoming an important part of its advanced nuclear platform, with a focus on building a reliable U.S. supply of critical radioisotopes. These isotopes are used in cancer diagnosis and treatment, advanced manufacturing, scientific research, space exploration and national security. Demand is growing rapidly, while global supply remains constrained because many important isotopes are sourced overseas or produced in aging facilities.
To address this supply gap, OKLO is creating an integrated isotope production platform using multiple approaches, including reprocessing existing materials and producing fresh isotopes in purpose-built reactors. By sourcing material through U.S. and international waste partnerships, the company aims to process waste into valuable isotopes while reducing reliance on fragile foreign supply chains. Its Idaho Radiochemistry Laboratory is expected to support early isotope output and operational learning.
OKLO’s long-term strategy involves a phased rollout across multiple sites. The Groves Isotope Test Reactor in Texas has received DOE approval for its Documented Safety Analysis, moving it into final pre-startup review, with readiness review and startup approval remaining. After approval, Groves can move toward fuel loading, startup testing and first criticality, targeted for July 2026. The multi-reactor isotope foundry in Idaho and Advanced Fuel Center in Tennessee are expected to support commercial-scale isotope production and fuel-cycle integration.
While OKLO is pursuing a vertically integrated strategy, rising isotope demand is creating opportunities for companies with existing nuclear expertise, medical-isotope capabilities and global supply networks. These players could benefit as healthcare, research, industrial and security applications require more dependable isotope availability.
Other Companies Tapping Isotope Demand
BWX Technologies (BWXT - Free Report) is strengthening its role in nuclear materials and isotope production, including medical isotopes such as Mo-99 and actinium-225. BWX Technologies benefits from government partnerships and a secure domestic supply chain. As isotope demand rises, BWX Technologies is positioned as a strategic U.S. supplier.
Meanwhile, Sotera Health (SHC - Free Report) , through its Nordion business, is a major supplier of cobalt-60 used in cancer treatment and medical sterilization. Sotera Health supports global healthcare needs through an established distribution network and long-term customer ties. With supply constraints continuing, Sotera Health remains well placed in the isotope market.
The Zacks Rundown on OKLO
Shares of Oklo have lost some 12% over the past year, underperforming the industry's growth.
Image Source: Zacks Investment Research
OKLO currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 24 brokerage firms.
Image Source: Zacks Investment Research
See how the Zacks Consensus Estimate for OKLO’s earnings has been revised over the past 90 days.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Why OKLO Is Betting Big on the Future of Nuclear Isotopes
Key Takeaways
Oklo Inc.’s (OKLO - Free Report) isotopes business is becoming an important part of its advanced nuclear platform, with a focus on building a reliable U.S. supply of critical radioisotopes. These isotopes are used in cancer diagnosis and treatment, advanced manufacturing, scientific research, space exploration and national security. Demand is growing rapidly, while global supply remains constrained because many important isotopes are sourced overseas or produced in aging facilities.
To address this supply gap, OKLO is creating an integrated isotope production platform using multiple approaches, including reprocessing existing materials and producing fresh isotopes in purpose-built reactors. By sourcing material through U.S. and international waste partnerships, the company aims to process waste into valuable isotopes while reducing reliance on fragile foreign supply chains. Its Idaho Radiochemistry Laboratory is expected to support early isotope output and operational learning.
OKLO’s long-term strategy involves a phased rollout across multiple sites. The Groves Isotope Test Reactor in Texas has received DOE approval for its Documented Safety Analysis, moving it into final pre-startup review, with readiness review and startup approval remaining. After approval, Groves can move toward fuel loading, startup testing and first criticality, targeted for July 2026. The multi-reactor isotope foundry in Idaho and Advanced Fuel Center in Tennessee are expected to support commercial-scale isotope production and fuel-cycle integration.
While OKLO is pursuing a vertically integrated strategy, rising isotope demand is creating opportunities for companies with existing nuclear expertise, medical-isotope capabilities and global supply networks. These players could benefit as healthcare, research, industrial and security applications require more dependable isotope availability.
Other Companies Tapping Isotope Demand
BWX Technologies (BWXT - Free Report) is strengthening its role in nuclear materials and isotope production, including medical isotopes such as Mo-99 and actinium-225. BWX Technologies benefits from government partnerships and a secure domestic supply chain. As isotope demand rises, BWX Technologies is positioned as a strategic U.S. supplier.
Meanwhile, Sotera Health (SHC - Free Report) , through its Nordion business, is a major supplier of cobalt-60 used in cancer treatment and medical sterilization. Sotera Health supports global healthcare needs through an established distribution network and long-term customer ties. With supply constraints continuing, Sotera Health remains well placed in the isotope market.
The Zacks Rundown on OKLO
Shares of Oklo have lost some 12% over the past year, underperforming the industry's growth.
OKLO currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 24 brokerage firms.
See how the Zacks Consensus Estimate for OKLO’s earnings has been revised over the past 90 days.
The company currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.